Nanobiotix ( ($NBTX) ) has issued an announcement. On October 1, 2025, Nanobiotix announced promising initial data from a Phase 1 study evaluating ...

Feasibility of endoscopic ultrasound-guided intratumoral injection was confirmed in 9 EADC patients with treated JNJ-1900 (NBTXR3) combined with photon CRT in cohort 1 and 4 EADC patients treated with ...

CRYPTICS study met the primary efficacy endpoint measure, 24-hour chest tube drainage (Difference in LS Means was 142.0 mL; 95.576% confidence ...

Ananya Joshi, a 2024 Northwestern University biotech graduate, left the US after job search struggles post-layoff.

A new study, led by researchers at the University of Liverpool, has revealed how pathogenic bacteria construct tiny ...

Regenerative Medical Solutions (RMS), a Wisconsin-based biotech company, has been awarded a peer-reviewed National Institutes ...

Kazia Therapeutics Limited (NASDAQ: KZIA), a clinical-stage biotechnology company developing innovative therapies for brain cancers, today announced its participation in a fully funded Australian ...

Russia’s Bion-M No.2 biosatellite, nicknamed “Noah’s Ark” for the diversity of life it carried, has completed its 30-day ...

Angel Yeast (SH600298), a global leader in yeast and biotechnology, today announced that its subsidiary Xizang Angel Zhufeng ...

NANOBIOTIX (Euronext: NANO - NASDAQ: NBTX - the "Company"), a late-clinical stage biotechnology company pioneering nanotherapeutic approaches ...

In a recent trial, verapamil showed a trend toward preserving insulin-producing beta cells in patients with Type 1 diabetes but failed to achieve statistical significance.